# A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer

> **NCT01472770** · PHASE2 · COMPLETED · sponsor: **Vejle Hospital** · enrollment: 49 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Gemcitabine + Capecitabine

## Key facts

- **NCT ID:** NCT01472770
- **Lead sponsor:** Vejle Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-05
- **Final completion:** 2014-05
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2014-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01472770

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01472770, "A Phase II Study of Gemcitabine and Capecitabine for Treatment Resistant, Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01472770. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*